

180 days. The implanted Ologen is supposed to undergo a complex enzymatic degradation by *in vivo* physiological proteases such as the collagenases present at the local site.⁷ The reason for the absence of biodegradation of Ologen in our patient is a matter of curiosity, unresolved at present. Occurrence of bleb encapsulation and formation of “ring of steel” when MMC-soaked Ologen implants were used is known, and is hypothesized due to prolonged localized effect of MMC and resultant excessive fibroblast proliferation in the surrounding.^{5,8} However, persistence of Ologen was not noted in these studies. Subconjunctival hyperplasia with Ologen has been noted in animal studies in the short-term.⁹

Ologen, by acting as a space-occupying lesion and possibly inducing localization of the bleb, could also be postulated to result in outflow resistance and bleb failure. On removal of the Ologen and revising trabeculectomy, a diffuse low-lying bleb had formed, achieving the desired control of IOP. Hence, one must consider that retention of Ologen itself could be contributory to bleb failure.

Footnotes and Disclosure:

The authors have no proprietary or commercial interest in any materials discussed in this article.

Harathy Selvan, Shikha Gupta, Prabhav Puri, Seema Sen, Viney Gupta

All India Institute of Medical Sciences, New Delhi, India

Correspondence to:

Harathy Selvan, MD: sharathy2012@gmail.com

REFERENCES

1. Sawchyn AK, Slabaugh MA. Innovations and adaptations in trabeculectomy. *Curr Opin Ophthalmol*. 2016;27:158–63.
2. Zelefsky JR, Hsu W-C, Ritch R. Biodegradable collagen matrix implant for trabeculectomy. *Expert Rev Ophthalmol*. 2008;3:613–7.
3. He M, Wang W, Zhang X, Huang W. Ologen implant versus mitomycin C for trabeculectomy: a systematic review and meta-analysis. *PLoS One*. 2014;9:e85782.
4. Yuan F, Li L, Chen X, Yan X, Wang L. Biodegradable 3D-porous collagen matrix (Ologen) compared with mitomycin C for treatment of primary open-angle glaucoma: results at 5 years. *J Ophthalmol*. 2015;2015. Article ID 637537.
5. Cillino S, Casuccio A, Di Pace F, Cagini C, Ferraro LL, Cillino G. Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up. *BMC Ophthalmol*. 2016;16:24.
6. Boey P-Y, Narayanaswamy A, Zheng C, et al. Imaging of blebs after phacotrabeculectomy with Ologen collagen matrix implants. *Br J Ophthalmol*. 2011;95:340–4.
7. Song M, Lee S, Choe D, Kim S, Roh YH, Rho S. Clinical and biological evaluations of biodegradable collagen matrices for glaucoma drainage device implantation. *Invest Ophthalmol Vis Sci*. 2017;58:5329–35.
8. Min JK, Kee CW, Sohn SW, Lee HJ, Woo JM, Yim JH. Surgical outcome of mitomycin C-soaked collagen matrix implant in trabeculectomy. *J Glaucoma*. 2013;22:456–62.
9. Niu W, Shen G, Yuan Y, et al. Biodegradable PTLGA terpolymers versus collagen implants used as an adjuvant in trabeculectomy in rabbit eye. *J Ophthalmol*. 2015;2015:737198.

Can J Ophthalmol 2019;54:e305–e308

0008-4182/17/\$-see front matter © 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jcjo.2019.03.004>

Late-onset lattice corneal dystrophy associated *TGFBI* p.H626R mutation in members of a Canadian family



Within the over 70 reported transforming growth factor-beta–induced (*TGFBI*) corneal dystrophy mutations,¹ more than 40 are associated with lattice corneal dystrophy (LCD), subtypes I, III, IIIA, and IIIB according to the Human Gene Mutation Database (QIAGEN, Hilden, Germany). This is a follow-up investigation to a study we published in 2018 in the *Canadian Journal of Ophthalmology* entitled *Trauma-induced exacerbation of epithelial-stromal TGFBI lattice corneal dystrophy*. This study reported 2 cases of post-laser-assisted in situ keratomileusis (LASIK) and postcorneal injury exacerbated late-onset LCD, attributed to a p.H626R mutation in the *TGFBI* protein.² In this follow-up study, we tested 17 additional family members, excluding the deceased female in Generation II (GENII-1), to assess the mutation penetration and identify asymptomatic carriers.

Lattice corneal dystrophy is characterized by the deposition of amyloid, primarily in the stroma, that produces a clinical appearance of thin, branching refractile lattice lines. Histology reveals fusiform deposits scattered throughout

the stroma, concentrated predominantly below the Bowman's layer.⁶ A number of mutations located predominantly in exon 14 of *TGFBI* are responsible for the many phenotypic variants of LCD.⁸ The mutation reported within, located in exon 14 of *TGFBI*, is caused by the single base pair change, c.1877A>G (CAT>CGT), resulting in an arginine (R) for histidine (H) substitution at codon 626. This particular mutation is typically associated with late-onset LCD type IIIB, with first symptoms exhibiting in the fourth to fifth decade of life. This mutation has been reported in China,^{4,5} France,^{6,8} India,⁹ Mexico,^{10,11} Poland,¹² Singapore,¹¹ Switzerland,⁷ the United Kingdom,³ the United States,¹² and Vietnam.¹³ This is the first study to report cases in an extended Canadian family of Italian descent.²

MATERIALS AND METHODS

Informed consent was obtained from 19 family members spanning 4 generations. Buccal cells were collected on iSwab (Mawi DNA Technologies, Hayward, Calif.) and Copan swabs (Copan Diagnostics, Brescia, Italy). Whole exome sequencing was carried out by Personalis (Menlo




Fig. 1—OCT images of proband's mother. (OD): OCT images of right eye. One deposit was noted on the LASIK flaps where the green arrow points. (DS): OCT images of left eye. At least 4 deposits were noted on the LASIK flaps where the green arrows point.

Park, Calif.) on the proband and his mother's samples and results confirmed by Sanger sequencing (ELIM Biopharm, Hayward, Calif.). Real-time polymerase chain reaction (PCR) primers and probes were designed using Thermo Fisher TaqMan Custom design tool (Thermo Fisher Scientific, Waltham, Mass.) and was used to test 17 family members. A family tree was constructed illustrating the genotype of each subject.

RESULTS

Proband and proband's mother

The proband, a 27-year-old of Italian descent, residing in Montreal, Canada, presented with symptoms of recurrent corneal erosions in his right eye 4 years after a tree branch injury. His best-corrected visual acuity was 20/25 bilaterally. His right eye (the injured eye) showed 3 epithelial defects within an area of lattice-like changes, and his left eye had a clear cornea with no lattice-like changes.²

The proband's 63-year-old mother had bilateral LASIK in 2003. Her right eye showed central lattice-like deposits, and the left eye demonstrated diffuse lattice-like changes.² Her optical coherence tomography (OCT) image of the right eye revealed a small deposit at the LASIK flap. The OCT image

of the left eye displayed more deposits at the LASIK flap (Fig. 1).

Whole exome sequencing revealed a *TGFBI* H626R mutation in both the proband and his mother. The results were confirmed by Sanger sequencing, c.1877A>G (CAT>CGT) A to G substitution (Fig. 2).

Family study

A family history of corneal dystrophy was obtained from the proband's mother. Additional family members were ascertained, and a family tree was constructed. Segregation of the H626R mutation in the family, determined by PCR analysis, indicated that 14 of the 19 family members carried a p. H626R heterozygous mutation. Five of the 14 were symptomatic and 9 were asymptomatic (Fig. 3). The age of onset varied from the fourth to the fifth decade, which is later than typically seen with other *TGFBI* mutations. The first and second generations, aged 52 to 92 years, were all symptomatic. Three of the 4 members had corneal transplants due to corneal opacity. The third and fourth generations, aged 6 to 45 years, were asymptomatic. The only symptomatic individual in this age group was the proband who acquired symptoms after corneal trauma. Therefore, early symptoms are usually caused by corneal injuries. One asymptomatic




Fig. 2—Sanger sequencing electropherogram. A heterozygous c.1877A>G mutation was confirmed (R), representing by 2 equal peaks of A and G. This nucleotide change resulted in an arginine for histidine amino acid substitution.




Fig. 3—Family tree. Family tree with test results of symptomatic and asymptomatic heterozygous *TGFBI* p.H626R mutation carriers and noncarriers. Each individual is numbered in a format as GEN#-#; for example, GENIV-3 means the individual belongs to Generation IV and his/her assigned number is 3. The deceased female, GENII-1, was symptomatic and diagnosed with LCD; however, she was not available for genetic testing.

individual in Generation III, #2 (GENIII-2), had bilateral LASIK surgery in 2004; however, the PCR test revealed that she was not a carrier of the mutation. All the children in the fourth generation at the time this data was collected exhibited no corneal abnormalities.

DISCUSSION

In this study, we expand upon the findings of our initial study,² which described exacerbation of late-onset LCD after LASIK surgery and corneal injury accompanying a *TGFBI* p.H626R mutation in an Italian Canadian family. *TGFBI* corneal dystrophy is an autosomal dominant disease with a 50% chance of inheriting the mutation from the parent who is a carrier. This is entirely consistent with the pattern seen in this family, with 14 of the 19 family members inheriting the mutation; fortunately, the GENIII-2 individual who had the LASIK surgery had not inherited the mutation. Therefore, the risk of her developing symptoms is minimal. In addition, all members of the first and second generation exhibited phenotypical symptoms. This indicated that the penetrance of this mutation is 100%. The findings presented here from a Canadian family expand the geographical distribution of this specific form of LCD to Canada. The family study reiterates the importance of performing genetic testing for both screening of LASIK surgery candidates and symptomatic corneal abnormality confirmation. Asymptomatic carriers should not have LASIK surgeries and should be counselled about the risk of corneal trauma to corneal health to avoid developing early onset LCD. A full family history should be carefully taken before LASIK surgeries.

SUPPLEMENTARY MATERIALS

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jco.2019.03.007.

Footnotes and Disclosure:

Tara McMullen is a consultant to Avellino Lab USA Inc, Director of the Biomedical Sciences Research Institute, and Professor of Personalised Medicine at University of Ulster, Coleraine, Northern Ireland, United Kingdom. Connie Chao-Shern is a PhD candidate at University of Ulster, Coleraine, Northern Ireland, United Kingdom, and an employee of Avellino Lab USA Inc, Menlo Park, Calif. The authors wish to thank the patients who supported our study unconditionally. We wish to thank University of Toronto and Avellino Labs for their contribution and collaboration. We would also like to acknowledge the contribution of Mr. Jun Heok Jang for carrying out the PCR experiments.

Connie Chao-Shern,^{*,†} Larry A. DeDionisio,[†] Clara C. Chan,[‡] M. Andrew Nesbit,^{*} C.B. Tara McMullen^{*}

^{*}Biomedical Sciences Research Institute, University of Ulster, Coleraine, United Kingdom; [†]Avellino Lab USA Inc, Menlo Park, Calif.; [‡]University of Toronto, Toronto, Ont.

Correspondence to:

Professor Tara McMullen: tara.mcmullen@ulster.ac.uk

REFERENCES

- García-Castellanos R, Nielsen NS, Runager K, et al. Structural and functional implications of human transforming growth factor β -induced protein, TGFBIp, in corneal dystrophies. *Structure*. 2017;25:1740–50.

- Nithianandan H, Chao-Sherm C, DeDionisio L, Moore T, Chan CC. Trauma-induced exacerbation of epithelial-stromal TGFBI lattice corneal dystrophy. *Can J Ophthalmol*. 2019;54:e47–9.
- Evans CJ, Davidson AE, Carnit N, et al. Genotype-phenotype correlation for TGFBI corneal dystrophies identifies p.(G623D) as a novel cause of epithelial basement membrane dystrophy. *Invest Ophthalmol Vis Sci*. 2016;57:5407–14.
- Yang J, Han X, Huang D, et al. Analysis of TGFBI gene mutations in Chinese patients with corneal dystrophies and review of the literature. *Mol Vis*. 2010;16:1186–93.
- Wang D, Yao Y, Zhang M, Chen J. Genetic and phenotypic investigation of a Chinese pedigree with lattice corneal dystrophy IIIB subtype. *Eye Sci*. 2013;28:144–7.
- Dighiero P, Niel F, Ellies P, et al. Histologic phenotype–genotype correlation of corneal dystrophies associated with eight distinct mutations in the TGFBI gene. *Ophthalmology*. 2001;30(108):818–23.
- Munier FL, Frueh BE, Orthenin-Girard P, et al. BIGH3 mutation spectrum in corneal dystrophies. *Invest Ophthalmol Vis Sci*. 2002;43:949–54.
- Schmitt–Bernard CF, Guittard C, Arnaud B, et al. BIGH3 exon 14 mutations lead to intermediate type I/IIIA of lattice corneal dystrophies. *Invest Ophthalmol Vis Sci*. 2000;41:1302–8.
- Chakravarthi SK, Kannabiran C, Sridhar MS, Vemuganti GK. TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients. *Invest Ophthalmol Vis Sci*. 2005;46:121–5.
- Nowińska AK, Wylegala E, Janiszewska DA, et al. Genotype-phenotype correlation of TGFBI corneal dystrophies in Polish patients. *Mol Vis*. 2011;17:2333–42.
- Elavazhagan M, Lakshminarayanan R, Zhou L, et al. Expression, purification and characterization of fourth FAS1 domain of TGFβ1p-associated corneal dystrophic mutants. *Protein Expr Purif*. 2012;84:108–15.
- Lai K, Reidy J, Bert B, Milman T. Spheroidal degeneration in H626R TGFBI variant lattice dystrophy: a multimodality analysis. *Cornea*. 2014;33:726–32.
- Chau HM, Ha NT, Cung LX, et al. H626R and R124C mutations of the TGFBI (BIGH3) gene caused lattice corneal dystrophy in Vietnamese people. *Br J Ophthalmol*. 2003;87:686–9.

Can J Ophthalmol 2019;54:e308–e311

0008-4182/17/\$-see front matter © 2019 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
<https://doi.org/10.1016/j.jco.2019.03.007>

How to knot bury and not break the suture: the 3-1-bury-1 knot



Suturing of a wound is typically performed for incisions that fail to seal after stromal hydration or after other anterior segment procedures, such as penetrating keratoplasty.^{1–4} On tying a suture of appropriate tension, rotation and burying of the knot is important to prevent foreign body sensation and irritation to the palpebral conjunctiva.^{3–6} However, the knot can break or slip during rotation and burying of the knot.

The 3-throw, “3-1-1” approach, also known as the surgeon’s knot, is a traditional suture tying technique employed routinely in ophthalmology.⁶ However, when tied, this knot typically has a cross-sectional area significantly larger than its accompanying needle tract. As a result, a surgeon may have difficulty burying the knot into the corneal stroma or limbal tissue. The force required to bury this knot may exceed the tensile strength of the suture, leading to suture breakage. Some alternatives, such as the “3-1”, the “2-1-1” square knot, the “1-1-1” slip knot, and “1-1-1-1” modified slip knot, have been used.^{3,6–8} These techniques reduce the size of the knot and, in the case of the slip and modified slip knot, allow adjustment of suture tension until locked.³ However, these knots tolerate significantly less tensile force. For instance, in one study, the modified slip knot tolerated 0.64 N before breakage and 0.37 N before slippage, whereas the surgeon’s knot tolerated 0.71 and 0.48 N, respectively.⁴ In another study, the slip knot and modified slip knot demonstrated greater than 2 times more slippage after 24 hours than the surgeon’s knot.⁷ Herein, we present an alternative technique for tying a 3-1-1 square knot, reducing its cross-sectional area while burying the knot, thus reducing the likelihood of suture breakage.

A 10-0 nylon suture is placed across the wound (Video 1). The first throw comprises 3 loops and may be adjusted to the

desired tension (Fig. 1A,B). The second throw uses 1 loop in the opposite direction to the first throw. This creates a locking square knot (Fig. 1C,D). The knot is buried (Fig. 1C,D). The third and final throw is a single loop that is tied in the opposite direction to the second throw to lock the knot securely (Fig. 1E). The ends of the sutures are then trimmed using a 75-blade. The final step pulls the knot from its buried position but may be buried once again with relative ease (Fig. 1F).

In the traditional 3-throw, 3-1-1 technique, the initial loops limit the suture from slipping, permitting the appropriate tension to be maintained during the second and third throws, each of which secures the knot further. This ultimately results in a strong knot that is resistant to breakage and unravelling. However, this technique has its disadvantages, including appropriate tensioning and its large size, making it more difficult to bury.

Attention must be made to bury all corneal and limbal knots to reduce corneal irritation. For these reasons, smaller knots have been developed (e.g., 3-1, 2-1-1 square knots, the 1-1-1 slip knot, and 1-1-1-1 modified slip knot). Each of these techniques produces a smaller knot that requires less force when burying.^{4,7,8} The slip knot and modified slip knot in particular offer the additional benefit of tension adjustment until after the third throw. The trade-off, however, is that these alternatives produce sutures with reduced tensile strength compared with the traditional 3-1-1 technique.^{4,8}

In the 3-1-bury-1 technique, the cross-sectional area of the knot is smaller after the second throw than that of the standard 3-1-1 knot. This reduced cross-sectional area allows the knot to be more easily rotated into the corneal stroma. This initial burying of the knot enlarges the suture needle tract. During the subsequent throw, the knot retracts from the corneal stroma but is easily rotated back into the previously widened path, thus minimizing the potential for suture breakage. Ultimately, this may limit the need to replace sutures, decrease operating time, and reduce associated complications.